Drug Profile
Research programme: anaesthetics - The Medicines Company
Latest Information Update: 17 Jan 2020
Price :
$50
*
At a glance
- Originator Annovation BioPharma
- Developer The Medicines Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anaesthesia
Most Recent Events
- 06 Jan 2020 The Medicines Company has been acquired by Novartis
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anaesthesia in USA (Parenteral)
- 04 Feb 2015 Annovation BioPharma has been acquired by The Medicines Company